- Home
- CKPT vs CMRX Comparison
CKPT vs CMRX Comparison
Compare CKPT & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- CMRX
- Stock Information
- Founded
- CKPT 2014
- CMRX 2000
- Country
- CKPT United States
- CMRX United States
- Employees
- CKPT N/A
- CMRX N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CKPT Health Care
- CMRX Health Care
- Exchange
- CKPT Nasdaq
- CMRX Nasdaq
- Market Cap
- CKPT N/A
- CMRX 77.0M
- IPO Year
- CKPT 2017
- CMRX 2013
- Fundamental
- Price
- CKPT $3.77
- CMRX $0.93
- Analyst Decision
- CKPT Strong Buy
- CMRX Strong Buy
- Analyst Count
- CKPT 2
- CMRX 1
- Target Price
- CKPT $12.00
- CMRX $11.00
- AVG Volume (30 Days)
- CKPT 946.5K
- CMRX 119.4K
- Earning Date
- CKPT 11-11-2024
- CMRX 11-08-2024
- Dividend Yield
- CKPT N/A
- CMRX N/A
- EPS Growth
- CKPT N/A
- CMRX N/A
- EPS
- CKPT N/A
- CMRX N/A
- Revenue
- CKPT $78,000.00
- CMRX $144,000.00
- Revenue This Year
- CKPT N/A
- CMRX $3,040.12
- Revenue Next Year
- CKPT $151,162.55
- CMRX N/A
- P/E Ratio
- CKPT N/A
- CMRX N/A
- Revenue Growth
- CKPT N/A
- CMRX N/A
- 52 Week Low
- CKPT $1.36
- CMRX $0.75
- 52 Week High
- CKPT $3.95
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- CKPT 84.67
- CMRX 60.78
- Support Level
- CKPT $2.37
- CMRX $0.80
- Resistance Level
- CKPT $2.54
- CMRX $0.98
- Average True Range (ATR)
- CKPT 0.27
- CMRX 0.05
- MACD
- CKPT 0.10
- CMRX 0.01
- Stochastic Oscillator
- CKPT 88.60
- CMRX 83.33
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.